Phase I Trial of Feasibility and Safety of Liver SBRT in Combination With Immune Checkpoint Inhibition in Patients With Metastatic Non-small Cell Lung Cancer

• Status: Not yet recruiting
• Trial end date: 2026-06-15

Summary

Determine the feasibility of liver stereotactic body radiation therapy (SBRT) given in combination with systemic therapy (immune checkpoint inhibitors) in adult patients with metastatic NSCLC with liver metastases.

• Phase: Phase 1

Details

• Lead Sponsor: VA Ann Arbor Healthcare System
• Collaborator: Lungevity
• Treatments: Pembrolizumab